Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke showdown: which Pre-Clot drug wins?

NCT ID NCT05728333

Disease control Sponsor: Xinqiao Hospital of Chongqing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different medicines given before a procedure to remove a blood clot from the brain in people having a major stroke. The goal is to see which medicine helps more people recover with little or no disability. About 800 adults who arrive at the hospital within 24 hours of stroke symptoms will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years or older. 2. Presenting with acute ischemic stroke symptom. 3. Time from onset to hospital arrival: * (1) within 4.5 hours * (2) 4.5-9.0 hours, image inclusion criteria for the EXTEND trial must be met * (3) \> 4.5 hours but within 24 hours, image inclusion criteria for the WAKE-UP trial must be met. 4. Eligible for intravenous thrombolysis. 5. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery, vertebrobasilar artery confirmed by CTA, MRA, or DSA. 6. Informed consent obtained from patients or their legal representatives. Exclusion Criteria: 1. CT or MR evidence of hemorrhage (the presence of micro-bleeds is allowed); 2. Contraindications of IV rt-PA or tirofiban; 3. Contraindication to radiographic contrast agents, nickel, titanium metals or their alloys; 4. Arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel; 5. Patients with a preexisting neurological or psychiatric disease that would confound the neurological functional evaluations; 6. CT or MRI evidence of mass effect or intracranial tumor (except small eningioma); 7. CT or MRI evidence of cerebral vasculitis; 8. CTA or MRA evidence of intracranial arteriovenous malformations or aneurysms; 9. Any terminal illness with life expectancy less than 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke with large vessel occlusion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke, acute ischemic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hangzhou First People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.